Float Short %

13.87

Margin Of Safety %

Put/Call OI Ratio

2.56

EPS Next Q Diff

-0.04

EPS Last/This Y

1.8

EPS This/Next Y

3.39

Price

143.98

Target Price

205.82

Analyst Recom

1.17

Performance Q

2.39

Relative Volume

0.99

Beta

0.61

Ticker: KRYS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	KRYS	150.26	1.47	0.09	14191
2025-08-18	KRYS	146.46	1.48	0.34	6272
2025-08-19	KRYS	143.74	1.54	1.50	6519
2025-08-20	KRYS	145.88	1.54	196.50	6536
2025-08-21	KRYS	145.52	1.99	2.00	7710
2025-08-22	KRYS	150.49	1.99	5.89	7723
2025-08-25	KRYS	146.95	2.04	24.30	7859
2025-08-26	KRYS	146.92	2.19	0.66	8250
2025-08-27	KRYS	147.49	2.16	3.84	8632
2025-08-28	KRYS	150.54	2.46	13.33	9475
2025-08-29	KRYS	147.87	2.63	5.12	9952
2025-09-02	KRYS	149.06	2.59	86.00	9830
2025-09-03	KRYS	150.31	2.73	0.31	10225
2025-09-04	KRYS	149.76	2.73	1.00	10244
2025-09-05	KRYS	150.49	2.72	0.06	10247
2025-09-08	KRYS	145.22	2.71	0.01	10269
2025-09-09	KRYS	140.91	2.62	0.13	10369
2025-09-10	KRYS	137.31	2.58	0.53	10410
2025-09-11	KRYS	144.18	2.48	0.02	10655
2025-09-12	KRYS	143.85	2.56	0.48	10571
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	KRYS	150.37	-13.0	-0.3	4.92
2025-08-18	KRYS	146.31	-13.0	-5.1	4.92
2025-08-19	KRYS	143.96	-13.0	-3.3	4.92
2025-08-20	KRYS	146.08	-13.0	2.3	4.92
2025-08-21	KRYS	145.61	-13.0	-0.7	4.92
2025-08-22	KRYS	150.49	-13.0	5.6	4.92
2025-08-25	KRYS	146.66	-13.0	-4.9	4.92
2025-08-26	KRYS	146.88	-13.0	-0.2	4.92
2025-08-27	KRYS	147.64	-13.0	0.6	4.92
2025-08-28	KRYS	150.76	-13.0	3.4	4.92
2025-08-29	KRYS	147.83	-13.0	-3.9	4.92
2025-09-02	KRYS	149.03	-13.0	1.3	4.92
2025-09-03	KRYS	150.18	-13.0	181.3	4.92
2025-09-04	KRYS	149.66	-13.0	176.8	4.92
2025-09-05	KRYS	150.27	-13.0	180.2	4.92
2025-09-08	KRYS	145.20	-13.0	165.6	4.92
2025-09-09	KRYS	141.09	-13.0	167.6	4.92
2025-09-10	KRYS	137.45	-13.0	168.3	4.92
2025-09-11	KRYS	144.36	-13.0	198.8	4.92
2025-09-12	KRYS	143.98	-13.0	177.7	4.92
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	KRYS	-4.69	0.01	13.67
2025-08-18	KRYS	-4.67	2.37	13.67
2025-08-19	KRYS	-4.69	2.37	13.67
2025-08-20	KRYS	-4.69	2.37	13.67
2025-08-21	KRYS	-4.69	2.37	13.67
2025-08-22	KRYS	-4.69	2.37	13.67
2025-08-25	KRYS	-4.69	0.45	13.67
2025-08-26	KRYS	-4.69	0.45	13.67
2025-08-27	KRYS	-4.69	0.45	14.01
2025-08-28	KRYS	-4.69	0.45	14.01
2025-08-29	KRYS	-4.69	0.45	14.01
2025-09-02	KRYS	-4.67	0.51	14.01
2025-09-03	KRYS	-4.67	0.51	14.01
2025-09-04	KRYS	-4.67	0.51	14.01
2025-09-05	KRYS	-4.67	0.51	14.01
2025-09-08	KRYS	-4.67	0.47	14.01
2025-09-09	KRYS	-4.67	0.47	14.01
2025-09-10	KRYS	-4.67	0.47	14.01
2025-09-11	KRYS	-4.67	0.47	13.87
2025-09-12	KRYS	-4.67	0.47	13.87
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

1.29

Avg. EPS Est. Current Quarter

1.12

Avg. EPS Est. Next Quarter

1.25

Insider Transactions

-4.67

Institutional Transactions

0.47

Beta

0.61

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

105

Fair Value

168.92

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

34.4

Max Drawdown 5-Year %

-53.4

Target Price

205.82

P/E

29.23

Forward P/E

18.32

PEG

0.51

P/S

11.58

P/B

3.99

P/Free Cash Flow

22.43

EPS

4.92

Average EPS Est. Cur. Y

4.92

EPS Next Y. (Est.)

8.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

40.85

Relative Volume

0.99

Return on Equity vs Sector %

-10.8

Return on Equity vs Industry %

2.4

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.19

EBIT Estimation

177.7

Krystal Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 275

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today

news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance

stock history KRYS – Krystal Biotech, Inc. invest stock market

stock prices KRYS premarket after hours

ticker KRYS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KRYS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y